SHANGHAI, NANJING, China and PLEASANTON, Calif., Sept. 18, 2025 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development, manufacturing, and ...
The FDA's endorsement of MRD negativity as a surrogate endpoint may influence future regulatory decisions and clinical trial designs in multiple myeloma. High-risk myeloma is defined by specific ...
The MarketWatch News Department was not involved in the creation of this content. SHANGHAI, NANJING, China and PLEASANTON, Calif., Sept. 18, 2025 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results